Glax­o­SmithK­line scraps two key mid-stage tri­als for their ICOS drug in the lat­est set­back for the field

An­oth­er ICOS can­cer drug pro­gram is run­ning in­to stormy weath­er, with more bad news for Glax­o­SmithK­line R&D chief Hal Bar­ron.

GSK put out word on Wednes­day evening that it has de­cid­ed to scrap two mid-stage tri­als for fe­ladil­imab (GSK3359609) — an in­ves­ti­ga­tion­al in­ducible T cell co-stim­u­la­to­ry (ICOS) ag­o­nist — which wasn’t a huge sur­prise af­ter Jounce got trounced with their mid-stage ef­fort for vo­prate­limab last fall.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER